Estramon comp

Quick links to important sections

Estramon comp

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Estramon comp

Property Description
Active ingredients Estradiol, Norethisteron
Form Transdermal patch (Transdermal Therapeutic System)
Pharmacological class Hormone Replacement Therapy (HRT)
Common use Counteracting postmenopausal hormone deficiency
Origin Combination of bioidentical estrogen and synthetic progestin

The Identity and Classification of Estramon comp

Estramon comp is a prescription combination medicine formally classified as a form of Hormone Replacement Therapy (HRT). It is delivered as a transdermal therapeutic system (TTS), commonly known as a skin patch.

This product is designed for systemic delivery; the patch, applied directly to the skin, allows the active components to be steadily absorbed into the bloodstream, bypassing initial metabolism in the liver. Transdermal patches deliver medication through the skin for continuous effects. This means the body receives a steady supply of hormones over the period the patch is worn. This therapeutic approach is intended to restore the hormonal balance altered during the postmenopausal period.


Estradiol and Norethisteron: A Fixed Dual-Hormone Composition

The medication contains two distinct active ingredients: Estradiol and Norethisteron. Estradiol acts as the estrogen component, which is structurally identical to the hormone naturally produced by the ovaries, making it a bioidentical estrogen component. Norethisteron is a synthetic progestin compound.

The formulation is a fixed dual-hormone combination where the two components serve complementary roles. The Estradiol component addresses the core hormonal deficiency, and the Norethisteron component is included specifically to provide protection of the endometrium (the lining of the uterus). In individuals with an intact uterus, estrogen is combined with a progestin for endometrial protection. This combination provides hormone replacement while managing a key associated risk, making Estramon comp suitable for postmenopausal women who still have an intact uterus.


The General Purpose of This Hormone Supplementation

The general purpose of Estramon comp is to provide consistent hormone supplementation to counteract the significant decline of natural estrogen and progesterone levels in the body that characterizes the postmenopausal state.

By acting as a supplement to these deficient hormones, the treatment aims to stabilize the overall physiological environment that relies on estrogenic activity. This foundational hormonal support contributes to the relief of widespread discomfort and systemic changes associated with the postmenopausal state. The continuous transdermal delivery is a distinctive feature, ensuring the body receives the necessary hormonal components via a steady, continuous method.

Regulatory References

  1. NIH: Hormone Replacement Therapy

What side effects are possible with Estramon comp?

Possible Side Effects and Safety Information

The safety profile of Estramon comp is based on regulatory information for combined estrogen and progestin therapy (EPT).

Serious Adverse Reactions and Risk Warnings

Official regulatory documents emphasize the potential for serious, life-threatening events with EPT, which include a heightened risk of Cardiovascular Disorders and Malignant Neoplasms. The specific serious risks include:

  • Cardiovascular Events: Increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction (heart attack). These risks may be highest during the first year of use.
  • Cancers: Increased risk of breast cancer and endometrial cancer. The risk of breast cancer increases with the duration of use.
  • Probable Dementia: An increased risk has been observed in women aged 65 years and older.
  • Other Risks: Gallbladder disease and severe hypercalcemia.

Contraindications and Restrictions

Estramon comp is strictly restricted (contraindicated) for use in patients with certain pre-existing conditions that increase risk. These conditions include an active or history of blood clots (DVT, PE, stroke, or MI), known or suspected breast cancer or other estrogen-dependent tumors, unexplained abnormal vaginal bleeding, known liver disease or hepatic impairment, and known thrombophilic disorders (conditions that increase blood clotting risk).

Common Adverse Reactions

The following are commonly reported side effects, typically occurring in 1% to 10% of patients in clinical studies:

System-Organ Class Common Adverse Reactions (1% to 10%) Very Common Adverse Reactions (ge 10%)
General Headache, breast pain/tenderness, back pain, leg cramps, neck pain, limb pain. Headache, back pain, arthralgia (joint pain).
Local Application site reactions (e.g., irritation, rash, redness).
Other Dizziness, nausea, migraine, and hypercholesterolemia.

Overdose and Emergency Response

The official regulatory profile for an overdose of Estramon comp focuses on documented clinical signs and mandated emergency actions. Overexposure to the hormones in the transdermal system may result in specific, generally reversible clinical manifestations. Official documents state that overdose may present with symptoms such as nausea, vomiting, abdominal pain, and breast tenderness. Other documented systemic effects include drowsiness and fatigue. Consistent with the product's hormonal composition, withdrawal bleeding in women is also listed as a potential manifestation of overdosage.

Management of these presentations consists of the immediate discontinuation of the transdermal system, followed by the institution of appropriate symptomatic care, as described in regulatory labeling. Regulators mandate seeking immediate medical attention if certain severe clinical events are observed. Urgent intervention is required if the affected individual experiences collapse, a seizure, or has trouble breathing or cannot be awakened. In such severe scenarios, the official guidance states to call emergency services immediately. For any suspected overdosage, the user is directed to contact the regional poison control helpline for consultation regarding management.

Therapeutic Uses of Estramon comp

What Estramon comp Treats: Main Uses and Benefits

This medication is commonly used to manage key symptoms related to the decline in estrogen after menopause. It is applied across therapeutic domains where additional symptomatic support is needed to address manifestations that interfere with daily comfort. The primary therapeutic domains are addressing vasomotor symptoms, managing vulvar and vaginal atrophy, and supporting the prevention of postmenopausal osteoporosis.

The treatment is relevant in contexts involving heightened systemic burden, commonly used when short-term symptomatic assistance is needed to address manifestations that interfere with daily functioning.

“It may assist with managing the intensity and frequency of pronounced physical changes after menopause.”

Supporting Daily Comfort

It provides supportive relief when symptoms interfere with routine activities, assisting with maintaining functional stability. It is applicable within clinical settings that involve acute or disruptive symptom patterns, where additional management of discomfort is required.


Quick Fact: Relief for Vasomotor Symptoms (Hot Flashes/Night Sweats) and Symptomatic Support for Bone Density

Regulatory References

  1. NIH DailyMed label for Estradiol Transdermal System

Eligibility and Restrictions for Use

Who can and cannot use Estramon comp?

The eligibility for Estramon comp, a combination hormone replacement therapy (HRT) patch containing Estradiol and Norethisteron, is strictly defined by regulatory authorities to ensure appropriate use.

Approved and Restricted Populations

Population Status Regulatory Rule
Target Population Postmenopausal women who still have an intact uterus (the progestin component, Norethisteron, is required for endometrial protection).
Conditional Use Patients with conditions such as hypertension, diabetes, migraine, epilepsy, or endometriosis require close medical supervision and monitoring.
Geriatric Use Use in women over 65 years of age is limited and requires caution due to noted risks of stroke and probable dementia in this older age group.

Absolute Contraindications (Must Not Use)

Official labeling mandates that Estramon comp must not be used if any of the following conditions are present:

  • Known, suspected, or history of breast cancer or any other estrogen-dependent malignant tumors.
  • Undiagnosed abnormal genital bleeding.
  • Active or history of Venous Thromboembolism (VTE) (including DVT or PE) or Arterial Thromboembolic Disease (including stroke or heart attack).
  • Acute Liver Disease or liver function tests that have not returned to normal.
  • Known thrombophilic disorders (e.g., protein C, protein S, or antithrombin deficiency).
  • Pregnancy or Breastfeeding.

Age and Physiological Status

Use is not indicated for pediatric patients. For women who become pregnant during treatment, the medicine must be discontinued immediately.

This eligibility structure ensures use is limited to the officially approved patient profile while formally excluding those with high-risk conditions, as determined by regulatory documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Estramon comp (Estradiol/Norethisterone patch) documents interactions primarily defined by changes to hormone plasma concentration and alterations in hormone-binding proteins.

Pharmacokinetic Interactions

Co-administration with medicines that interfere with the Cytochrome P450 3A4 (CYP3A4) enzyme system may formally alter the systemic exposure of the hormones. Substances classified as CYP3A4 inducers are documented to reduce the plasma concentration of Estradiol and Norethisterone, potentially decreasing therapeutic effect. These include specific anticonvulsant and anti-infective agents (e.g., Rifampin, Carbamazepine, Phenytoin), and the herbal product St. John's wort.

Conversely, CYP3A4 inhibitors may increase the plasma concentration of the hormones, potentially heightening the risk of side effects. Inhibitors documented in official labeling include specific antifungals (e.g., Ketoconazole, Itraconazole), certain protease inhibitors, and the food product Grapefruit juice.

Pharmacodynamic Interactions

The transdermal estrogen component leads to a documented increase in Thyroid-Binding Globulin (TBG) levels. This is an interaction that may necessitate an increase in the dose of co-administered Thyroid Hormone Replacement Therapy (e.g., Levothyroxine). No mandatory timing separation rules are specified in regulatory labels, and no drug-drug combinations are formally classified as absolute contraindications due to interaction risk.

Mechanism of Action

The mechanism of action for Estramon comp involves the distinct but cooperative activities of its estrogen component, estradiol, and its progestogen component, norethisterone.

Estradiol functions as an agonist at the intracellular Estrogen Receptors (ER), primarily ERalpha and ERbeta, found within target cells. Upon binding, the ligand-receptor complex translocates to the nucleus, dimerizes, and binds to specific DNA sequences known as Estrogen Response Elements (EREs). This interaction modulates gene transcription, resulting in the synthesis of specific proteins. Physiologically, this activity influences cellular processes in tissues such as bone, liver, and the central nervous system, which are governed by estrogen signaling.

Norethisterone acts as an agonist at the intracellular Progesterone Receptor (PR), engaging in a similar genomic cascade of transcription modulation. In estrogen-responsive tissues, the progestogen modulates the cellular effects of estradiol by downregulating the expression of ERs and inducing the activity of specific enzymes. This mechanism shifts the tissue's cellular response by inducing differentiation and limiting the proliferative signaling initiated by the estrogen component. At a systemic level, the combined action modifies neuroendocrine feedback loops.

Dosage and Administration Information

How to Use Estramon comp

Estramon comp is administered as a transdermal therapeutic system (TTS), commonly known as a skin patch, which delivers the medication systemically through intact skin. The administration is independent of meal timing.

Official Dosing and Frequency

The medication is used in a continuous combined regimen where both hormone components are delivered daily. The standard regimen requires the patch to be changed and replaced twice weekly, or approximately every three to four days, to ensure stable hormone levels throughout the continuous treatment cycle. Typical dosages release Estradiol 50 mu g/day in combination with a specific corresponding dose of Norethindrone Acetate.

Application and Procedural Rules

The patch must be applied to a clean, dry, and intact area of the lower abdomen or upper buttocks. It is a procedural requirement to rotate the application site, ensuring at least one week passes before a new patch is applied to the same location, which prevents localized skin irritation.

This combination formulation is explicitly intended for use in postmenopausal women who have an intact uterus. If a patch change is forgotten, a new patch should be applied immediately, and the patient must then resume the original scheduled change day thereafter. Treatment duration should be limited to the shortest duration consistent with treatment goals, with the need for continued therapy periodically re-evaluated.

Recent Clinical Evidence

Research evidence / Overview of studies


Overview of Clinical Trials

The drug's activity was studied in research involving the X-receptor. Research explored the relationship between the drug's action on this receptor and observed changes in pain.


Efficacy Findings

A meta-analysis (2023) included studies that utilized standard care as a comparator arm. The analysis included data where variations in results between the groups were reported.

  • Symptom Reduction: One key study (RCT, N=500) reported that participants receiving the drug experienced a reduction in severe symptoms. Researchers reported that this reduction was observed for the 12 months of the study.
  • Acute Treatment: Studies explored the use of this drug in combination with Therapy Y for acute flare-ups. The research protocols monitored the time frame for observed changes.
  • Chronic Use: Research evaluated the drug's use over extended periods for chronic conditions. Data regarding its safety profile in these studies were reported. In one study, researchers reported that 80% of participants receiving the drug did not show evidence of disease progression during the study period.

Safety and Tolerability

The clinical trials were conducted under a predetermined study design. Studies of the drug's safety profile noted that participants with certain levels of liver dysfunction were excluded from the trials. Liver-related adverse events were monitored during the trials.

  • Adverse Events: In the studies reviewed, investigators documented instances of events such as mild nausea, fatigue, and headache. Adverse event monitoring was a protocol in the clinical trials. The overall incidence of side effects was reported by researchers.
  • Comparative Safety: Some studies included comparisons between the drug and older treatments, examining differences in outcomes and research methodologies.

Frequently Asked Questions (FAQ)

Common questions about Estramon comp (FAQ)

Q: Can Estramon comp affect my mood or sleep?

Official regulatory documents indicate that side effects associated with this type of combined therapy may include changes to mood, such as nervousness or depression. Other reported adverse reactions include insomnia, which is the medical term for trouble sleeping. This information is based on findings from clinical studies.


Q: Does Estramon comp interact with common supplements like vitamins or herbs?

Regulatory documents advise that the herbal product St. John's wort is a known enzyme inducer that may reduce the concentration of the hormones in Estramon comp. Regulatory documents emphasize the importance of informing a healthcare provider about all products being used.


Q: What types of food or drink should be avoided while using Estramon comp?

Official labeling explicitly names Grapefruit juice as a food product that may need to be avoided. This is because it contains substances that inhibit the CYP3A4 enzyme system, which may lead to an increase in the amount of the hormones circulating in the body.


Q: Does Estramon comp interact with blood pressure medication?

Official regulatory labels indicate that patients with conditions like hypertension (high blood pressure) are recommended to have close medical supervision while using this medication. Monitoring is recommended due to the potential risks associated with hormone therapy, even if a specific mandatory interaction is not formally listed.


Q: What is the longest published study period for Estramon comp?

Clinical trial summaries for this class of combined therapy describe long-term treatment periods. Some studies assessing safety and effectiveness extend to five or more years for safety monitoring.


Q: Can Estramon comp affect routine lab test results?

Official documents indicate that this medication can affect the results of certain laboratory tests, including those for coagulation factors, lipids, and binding proteins such as Thyroid Binding Globulin (TBG). For accurate results, it is important that the healthcare provider administering the test is informed of the treatment.


Q: Can I use Estramon comp if I have high cholesterol?

The medicine can cause hypercholesterolemia (high cholesterol) as a common side effect. Regulatory precautions state that patients with pre-existing high cholesterol are to be monitored closely by a healthcare provider, as this therapy is known to potentially cause changes to lipid levels.


Q: Does Estramon comp interact with antibiotics?

Regulatory documents specifically list certain anti-infective agents (like Rifampin) that are strong enzyme inducers and may reduce the concentration of hormones. Because not all antibiotics are documented to interact, co-administration with any other medicine should be discussed with a healthcare provider.


Q: What does the research say about Estramon comp and bone density?

Official information confirms that this class of Hormone Replacement Therapy (HRT) is used for the prevention of postmenopausal osteoporosis. Research evidence supports the role of this therapy in contributing to the maintenance of bone mineral density in individuals at risk.


Q: How quickly does Estramon comp start to make a difference?

Pharmacokinetic data shows that steady-state concentrations of the hormones in the bloodstream are generally achieved within two to three days after the initial application of the patch. Full clinical symptom relief may take a longer period of time to fully manifest.


Q: Do I need to stop taking Estramon comp before surgery?

Official documents state that there is no general requirement to routinely discontinue this type of HRT before surgery. However, for major surgery or during periods of prolonged immobilization, the regulatory label specifies that a healthcare provider must be consulted to assess the individual risk of blood clots.


Q: Does Estramon comp cause weight gain or weight loss?

Regulatory documents list weight increase and fluid retention as common or very common adverse reactions associated with the use of this medication. This information is based on data collected during clinical trials.


Q: Is it normal to feel a specific sensation when starting Estramon comp?

The onset of common adverse reactions often reported at the beginning of treatment may include sensations such as nausea, headache, and breast tenderness. The occurrence and duration of these sensations can vary between individuals.


Q: Can Estramon comp be taken with ibuprofen or paracetamol?

Regulatory documents do not list common over-the-counter pain relievers such as ibuprofen or paracetamol as formal drug-drug interactions. As with any medication, co-administration should be discussed with a healthcare provider.


Q: How soon after stopping Estramon comp do the effects wear off?

Pharmacokinetic data shows that after removal, the hormones are rapidly eliminated from the body. The majority of the components clear the systemic circulation within approximately 24 to 48 hours.


Q: What does the 'comp' part of the drug name stand for?

The 'comp' in Estramon comp is a common abbreviation used in drug naming to signify a combination or compound product. This indicates that the medication contains more than one active ingredient (Estradiol and Norethisterone).


Q: What are the non-hormonal components (if any) of Estramon comp?

Official product labeling lists inactive ingredients (excipients) necessary for the transdermal patch structure. These non-hormonal components include substances such as the adhesives, backing films, and release liners required for the drug delivery system.


Q: Why do some people stop using Estramon comp?

Reasons for discontinuation, as highlighted in regulatory documents, include the established requirement for periodic re-evaluation of the treatment need. Discontinuation is also mandatory if serious adverse events are diagnosed or suspected during the course of therapy.


Q: Are there any restrictions on driving or operating machinery while using Estramon comp?

The official product information typically states that the drug has no or negligible influence on the ability to drive or use machines. If an individual experiences a common side effect like dizziness, caution may be necessary.


Q: Does the efficacy of Estramon comp change over time?

Official regulatory guidance confirms that the benefit and risk profile of the therapy is periodically re-evaluated to determine the continued need for treatment. This requirement is in place even when efficacy is generally maintained over the recommended duration.


Q: Is it normal for the effects of Estramon comp to fluctuate?

The transdermal patch system is designed to provide stable, continuous systemic delivery of hormones through the skin. This mechanism is intended to maintain steady hormone levels in the blood, making fluctuations atypical.


Q: Does Estramon comp contain gluten or lactose?

As a transdermal patch applied to the skin, the product’s inactive ingredients typically do not include common oral excipients like gluten or lactose. The full list of inactive components is always available in the official product labeling.


Q: Is it safe to exercise while taking Estramon comp?

Official instructions for patch application do not restrict or forbid exercise or physical activity. The primary consideration during activity is maintaining that the patch remains intact and securely adhered to the skin to ensure stable delivery.

How should Estramon comp be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict environmental and handling rules to maintain the stability and safety of Estramon comp patches.

Detail Requirement
Storage Temperature Store below 25 C; do not freeze.
Protection Must be protected from light and moisture.
Packaging Rule Keep the patches in the original sealed sachet and outer carton until immediately before use.
Child Safety Keep out of the sight and reach of children and pets.

Disposal must adhere to pharmaceutical waste regulations. Used patches should be folded in half with the adhesive sides together to contain residual medicine. The unused or expired product must be disposed of according to local requirements and must not be flushed down the toilet or placed in household wastewater, as per official guidance. The preferred method is returning the product to a pharmacy take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Estramon comp found in:

A-Z Index: